Abstract
The focus of
this presentation will be to discuss how ATCC’s latest advanced cancer models
can be used effectively for pre-clinical translational research. The presentation
will focus on both lung and pancreatic cancers, which are among the most
prevalent cancer types. We will discuss the latest disease relevant models,
which can be utilized by researchers in these fields.
Lung cancer
currently accounts for 21% of all cancer deaths in the UK. Unlike the majority
of cancers the net survival for all genders has not increased by much since the
1970s. Pancreatic cancer similarly has a relatively poor prognosis, with a net
5-year survival rate of approximately 5%. The reasons for this lack of success
in finding adequate treatments are multifactorial. However, it is well
recognized that advanced pre-clinical cancer models are needed to provide more physiologically
relevant representations of the diseases
in-vivo.
A key aim of
ATCC is to provide advanced cancer models to help researchers to bridge the gap
between bench and bedside. This presentation will provide a brief overview of
several of the advanced models that ATCC has developed for the benefit of lung
and pancreatic cancer researchers. These include physiologically-relevant hTERT
immortalized cell lines, primary cells, conditionally reprogrammed cells and
cancer organoids from the Human Cancer Models Initiative (HCMI).
